Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-106565
Filing Date
2025-08-11
Accepted
2025-08-11 16:15:57
Documents
70
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q olma-20250630.htm   iXBRL 10-Q 3244239
2 EX-10.1 olma-ex10_1.htm EX-10.1 33521
3 EX-10.2 olma-ex10_2.htm EX-10.2 53925
4 EX-31.1 olma-ex31_1.htm EX-31.1 16685
5 EX-31.2 olma-ex31_2.htm EX-31.2 16680
6 EX-32.1 olma-ex32_1.htm EX-32.1 14306
  Complete submission text file 0000950170-25-106565.txt   10308230

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT olma-20250630.xsd EX-101.SCH 966114
72 EXTRACTED XBRL INSTANCE DOCUMENT olma-20250630_htm.xml XML 1964890
Mailing Address 780 BRANNAN STREET SAN FRANCISCO CA 94103
Business Address 780 BRANNAN STREET SAN FRANCISCO CA 94103 (415) 651-3316
Olema Pharmaceuticals, Inc. (Filer) CIK: 0001750284 (see all company filings)

EIN.: 300409740 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39712 | Film No.: 251202201
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)